FDA’s Accelerated Approval of Drug for Tumors With dMMR Deficiency (Advanced Solid Tumors)
August 19, 2021
We are pleased to report of a promising development for appendix cancer patients with a tumor identified as having a mismatch repair deficiency (or “dMMR”). This week, FDA granted accelerated approval for a drug to treat recurrent or advanced solid tumors having a dMMR for which patients have no satisfactory treatment options. Specifically, FDA has granted approval to GlaxoSmithKline’s drug...